How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/non-small-cell-lung-cancer-positive-for-epidermal-growth-factor-receptor-expression.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Non-small cell lung cancer, positive for epidermal growth factor receptor expression — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Non-small cell lung cancer, positive for epidermal growth factor receptor expression (disease) competitive landscape: 7 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

7 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Non-small cell lung cancer, positive for epidermal growth factor receptor expression, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Vizimpro	dacomitinib	Pfizer		Epidermal growth factor receptor	2018-01-01
Gilotrif	afatinib	Boehringer Ingelheim	Kinase Inhibitor [EPC]	Epidermal growth factor receptor	2013-01-01
Iressa	gefitinib	Pfizer Inc.	Kinase Inhibitor [EPC]	Epidermal growth factor receptor	2003-01-01
Tagrisso	Tagrisso	Suzhou Genhouse Bio Co., Ltd.		Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma, Cysteine--tRNA ligase, cytoplasmic, Dipeptidyl peptidase 1
Gilotrif	Gilotrif	Seoul St. Mary's Hospital		Citron Rho-interacting kinase, Adenosine kinase, Casein kinase I isoform epsilon
dacomitinib hydrate	dacomitinib-hydrate	Pfizer Inc.	The usual adult starting dosage for oral use is 45mg of dacomitinib hydrate once daily. The dose sho	Cyclin-G-associated kinase, Receptor-interacting serine/threonine-protein kinase 2, Receptor-interacting serine/threonine-protein kinase 3
Iressa	Iressa	David Adelstein		Citron Rho-interacting kinase, Ferrochelatase, mitochondrial, Mitogen-activated protein kinase 4

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Pfizer Inc. · 3 drugs in Non-small cell lung cancer, positive for epidermal growth factor receptor expression
Boehringer Ingelheim · 1 drug in Non-small cell lung cancer, positive for epidermal growth factor receptor expression
David Adelstein · 1 drug in Non-small cell lung cancer, positive for epidermal growth factor receptor expression
Pfizer · 1 drug in Non-small cell lung cancer, positive for epidermal growth factor receptor expression
Seoul St. Mary's Hospital · 1 drug in Non-small cell lung cancer, positive for epidermal growth factor receptor expression
Suzhou Genhouse Bio Co., Ltd. · 1 drug in Non-small cell lung cancer, positive for epidermal growth factor receptor expression

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Non-small cell lung cancer, positive for epidermal growth factor receptor expression:

Cite this brief

Drug Landscape (2026). Non-small cell lung cancer, positive for epidermal growth factor receptor expression — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/non-small-cell-lung-cancer-positive-for-epidermal-growth-factor-receptor-expression. Accessed 2026-06-10.

Non-small cell lung cancer, positive for epidermal growth factor receptor expression full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing